Express Pharma

JUNE 5, 2023

GlobalData’s latest report, ‘Myelofibrosis: Eight-Market Drug Forecast and Market Analysis,’ reveals that the MF market will grow from $2.39 billion in 2031 across the 8MM, registering a compound annual growth rate (CAGR) of 1.9 billion in 2021 to $2.89 per cent, driven by the approvals of nine pipeline agents.

Drug Development 97

Drug Development Biosimilars Compounding 97

European Pharmaceutical Review

JULY 4, 2024

4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. 13 Currently, over 350 herbal remedies have been granted a THR licence.

Drug Development 103

Drug Development Biosimilars Documentation Labelling 103

pharmaphorum

FEBRUARY 9, 2021

Researchers can use the information to help better target drug development and to support clinical trials. Since 2011, the company has been designing solutions that accelerate rare disease research and create lasting inter-sector partnerships across the globe. A Decade of Experience.

Compounding 98

Compounding Pharmaceutical Companies Pharmaceutical Companies Drug Development 98

European Pharmaceutical Review

JANUARY 29, 2024

17 Accelerating drug development The first issue of 2023 , 18 dealt with accelerating drug development. The FDA, in its “Overview of Major Quality Deficiencies and Approaches Available in GDUFA III” (generic drug user fee amendments) identified dissolution testing as one of its major quality deficiencies during 2023.

Drug Development 111

Drug Development Vaccines Compounding 111